Potential Side Effects and Risks Tesamorelin Side Effects Common side effects may include: Injection site reactions (pain, redness) Joint pain or muscle aches Mild gastrointestinal symptoms More serious risks include: Elevated fasting blood glucose Not recommended for patients with active malignancies See official FDA drug label: Tesamorelin (Egrifta) Prescribing Information Ipamorelin Side Effects Ipamorelin is generally well-tolerated
Currently, in addition to LY3463251, several other GDF-15 agonists are being assessed in early-stage clinical trials, including NNC0247-0829 and JNJ-9090/CIN-109, among others
Patients should be advised to maintain regular contact with their diabetes care team and report any patterns of hypoglycaemia (blood glucose below 4.0 mmol/L) or persistent hyperglycaemia
Furthermore, the insecticide detection rate results in higher in the epigeal parts, while plants with roots and rhizomes are more likely to be polluted by organochlorines and growth regulators (Rai et al., 2008)
GLP-1 Pipeline Update: February 2026 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid
